» Articles » PMID: 35690784

Translational Landscape of Glioblastoma Immunotherapy for Physicians: Guiding Clinical Practice with Basic Scientific Evidence

Overview
Journal J Hematol Oncol
Publisher Biomed Central
Specialties Hematology
Oncology
Date 2022 Jun 11
PMID 35690784
Authors
Affiliations
Soon will be listed here.
Abstract

Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the most difficult cancers to treat in both the primary and recurrent settings. GBM presents a unique therapeutic challenge given the immune-privileged environment of the brain and the aggressive nature of the disease. Furthermore, it can change phenotypes throughout the course of disease-switching between mesenchymal, neural, and classic gene signatures, each with specific markers and mechanisms of resistance. Recent advancements in the field of immunotherapy-which utilizes strategies to reenergize or alter the immune system to target cancer-have shown striking results in patients with many types of malignancy. Immune checkpoint inhibitors, adoptive cellular therapy, cellular and peptide vaccines, and other technologies provide clinicians with a vast array of tools to design highly individualized treatment and potential for combination strategies. There are currently over 80 active clinical trials evaluating immunotherapies for GBM, often in combination with standard secondary treatment options including re-resection and anti-angiogenic agents, such as bevacizumab. This review will provide a clinically focused overview of the immune environment present in GBM, which is frequently immunosuppressive and characterized by M2 macrophages, T cell exhaustion, enhanced transforming growth factor-β signaling, and others. We will also outline existing immunotherapeutic strategies, with a special focus on immune checkpoint inhibitors, chimeric antigen receptor therapy, and dendritic cell vaccines. Finally, we will summarize key discoveries in the field and discuss currently active clinical trials, including combination strategies, burgeoning technology like nucleic acid and nanoparticle therapy, and novel anticancer vaccines. This review aims to provide the most updated summary of the field of immunotherapy for GBM and offer both historical perspective and future directions to help inform clinical practice.

Citing Articles

Applications of polymeric nanoparticles in drug delivery for glioblastoma.

Liu S, Tan B, Wang F, Yu Y Front Pharmacol. 2025; 15():1519479.

PMID: 39834835 PMC: 11742935. DOI: 10.3389/fphar.2024.1519479.


S100A11 is a potential prognostic biomarker and correlated with tumor immunosuppressive microenvironment in glioma.

Fan J, Wang X, Yang X Medicine (Baltimore). 2024; 103(51):e40701.

PMID: 39705426 PMC: 11666167. DOI: 10.1097/MD.0000000000040701.


Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma.

Jimenez R, Constantinescu A, Yazir M, Alfonso-Triguero P, Pequerul R, Pares X Int J Mol Sci. 2024; 25(21).

PMID: 39519068 PMC: 11546810. DOI: 10.3390/ijms252111512.


Immunotherapy for glioblastoma: current state, challenges, and future perspectives.

Liu Y, Zhou F, Ali H, Lathia J, Chen P Cell Mol Immunol. 2024; 21(12):1354-1375.

PMID: 39406966 PMC: 11607068. DOI: 10.1038/s41423-024-01226-x.


Type I interferon signaling regulates myeloid and T cell crosstalk in the glioblastoma tumor microenvironment.

Lim J, La J, Kim H, Kang I, Kang B, Ku K iScience. 2024; 27(9):110810.

PMID: 39286510 PMC: 11404196. DOI: 10.1016/j.isci.2024.110810.


References
1.
Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C . Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol. 2011; 22(2):159-74. PMC: 8029175. DOI: 10.1111/j.1750-3639.2011.00515.x. View

2.
Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

3.
Cugurra A, Mamuladze T, Rustenhoven J, Dykstra T, Beroshvili G, Greenberg Z . Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science. 2021; 373(6553). PMC: 8863069. DOI: 10.1126/science.abf7844. View

4.
Unger J, Hershman D, Fleury M, Vaidya R . Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. JAMA Oncol. 2019; 5(3):326-333. PMC: 6439841. DOI: 10.1001/jamaoncol.2018.5953. View

5.
Narayana A, Gruber D, Kunnakkat S, Golfinos J, Parker E, Raza S . A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 2011; 116(2):341-5. DOI: 10.3171/2011.9.JNS11656. View